4889 Renascience Inc.レナサイエンスTSE Growth / Pharmaceuticals
0 posts
Renascience Inc. (4889) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Renascience Inc. (4889) Stock Price HistoryNear a 52-week low
Renascience Inc. closed at ¥786 on Nov 20, 2026, −22.5% over 1 month, −59.5% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥77,515 today (−22.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved −22.5%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥786 | −48 | −5.76% |
| Nov 19 (Thu) | ¥834 | −4 | −0.48% |
| Nov 18 (Wed) | ¥838 | −9 | −1.06% |
| Nov 17 (Tue) | ¥847 | −28 | −3.20% |
| Nov 16 (Mon) | ¥875 | −21 | −2.34% |
| Nov 13 (Fri) | ¥896 | −3 | −0.33% |
| Nov 12 (Thu) | ¥899 | +6 | +0.67% |
| Nov 11 (Wed) | ¥893 | +36 | +4.20% |
| Nov 10 (Tue) | ¥857 | +55 | +6.86% |
| Nov 9 (Mon) | ¥802 | +28 | +3.62% |
If you had invested ¥100,000 3 months ago, it would be worth ¥57,456 today (−42.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −42.5%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥786 | −48 | −5.76% |
| Nov 19 (Thu) | ¥834 | −4 | −0.48% |
| Nov 18 (Wed) | ¥838 | −9 | −1.06% |
| Nov 17 (Tue) | ¥847 | −28 | −3.20% |
| Nov 16 (Mon) | ¥875 | −21 | −2.34% |
| Nov 13 (Fri) | ¥896 | −3 | −0.33% |
| Nov 12 (Thu) | ¥899 | +6 | +0.67% |
| Nov 11 (Wed) | ¥893 | +36 | +4.20% |
| Nov 10 (Tue) | ¥857 | +55 | +6.86% |
| Nov 9 (Mon) | ¥802 | +28 | +3.62% |
If you had invested ¥100,000 6 months ago, it would be worth ¥50,612 today (−49.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved −49.4%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥786 | −19.1% |
| Oct 2026 | ¥971 | −17.1% |
| Sep 2026 | ¥1,171 | −10.3% |
| Aug 2026 | ¥1,306 | −12.1% |
| Jul 2026 | ¥1,485 | −4.7% |
| Jun 2026 | ¥1,558 | +13.3% |
| May 2026 | ¥1,375 | +17.2% |
If you had invested ¥100,000 1 year ago, it would be worth ¥40,515 today (−59.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −59.5%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥786 | −19.1% |
| Oct 2026 | ¥971 | −17.1% |
| Sep 2026 | ¥1,171 | −10.3% |
| Aug 2026 | ¥1,306 | −12.1% |
| Jul 2026 | ¥1,485 | −4.7% |
| Jun 2026 | ¥1,558 | +13.3% |
| May 2026 | ¥1,375 | +17.2% |
| Apr 2026 | ¥1,173 | −30.1% |
| Mar 2026 | ¥1,678 | −13.8% |
| Feb 2026 | ¥1,946 | +31.5% |
| Jan 2026 | ¥1,480 | +4.5% |
| Dec 2025 | ¥1,416 | −36.2% |
| Nov 2025 | ¥2,220 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥171,616 today (+71.6%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved +71.6%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥786 | −44.5% |
| 2025 | ¥1,416 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥89,624 today (−10.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −10.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥786 | −44.5% |
| 2025 | ¥1,416 | ― |
If you had invested ¥100,000 in Sep 2021, it would be worth ¥95,157 today (−4.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +91.6%, while this stock moved −4.8%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥786 | −44.5% |
| 2025 | ¥1,416 | +376.8% |
| 2024 | ¥297 | −31.6% |
| 2023 | ¥434 | +18.3% |
| 2022 | ¥367 | −46.3% |
| 2021 | ¥683 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Sep 2021). Please check the latest prices before trading.
Renascience Inc. (4889) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Renascience Inc. (4889)
Business overview
To solve problems in clinical practice, the company is developing a range of modalities, including drugs, medical devices and AI-based software as a medical device. Aiming to realize new medical care that lets people enjoy physical and mental health throughout their lives, it is working on treatments for diseases that affect healthy life expectancy, such as cancer, cardiovascular disease, respiratory disease and diabetes, as well as for diseases affecting women and children. It is also focusing on research in the longevity field, such as senolytic drugs that remove senescent cells. Its R&D began with the development of drugs such as PAI-1 inhibitors discovered through computer engineering and small-molecule screening.
Summarized from the annual securities report (fiscal year ended March 2026) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 3.43x | Above the sector median of 1.86x (No. 59 from the lowest) |
|---|---|---|
| ROE | -17.38% | No. 40 in the sector (highest first); median 4.17% |
| Market cap | ¥10.8 bn | No. 44 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥2,220 | 2025/11/28 |
|---|---|---|
| 52-week low | ¥774 | 11/6 |
| Current position | 0.8% | Where the low is 0% and the high is 100% (close on 11/20: ¥786) |
| Year to date | -44.5% | No. 64 of 77 in the sector (best first) |
| 1 year | -59.5% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/11 15:302027年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)
- 10/05 15:30根治切除不能悪性黒色腫(メラノーマ)に対するニボルマブとPAI-1阻害薬RS5614併用の第三相試験における症例登録完了のお知らせ
- 09/29 15:30慢性骨髄性白血病に対するチロシンキナーゼ阻害薬(TKI)併用PAI-1阻害薬RS5614の第三相試験における患者投与完了のお知らせ
- 09/25 15:30皮膚血管肉腫治療薬の希少疾病用医薬品指定に関するお知らせ
Filings from the past 12 months (4).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the Renascience Inc. board
More Japanese stocks in English
- iShares Yen Appreciation Focus ETF488A
- Tsubota Laboratory Incorporated4890
- TMS Co.,Ltd.4891
- Cyfuse Biomedical K.K.4892
- Noile-Immune Biotech Inc.4893
- Cuorips Inc.4894
- K Pharma,Inc.4896
- TSE REIT Logistics Focus ETF489A
- KONICA MINOLTA,INC.4902
- SENSE TRUST Co.,Ltd.490A
- Lion Corporation4912
- TAKASAGO INTERNATIONAL CORPORATION4914